Content area

|
|

Behandling af primær og recidiverende ovariecancer

Forfatter(e)
Mikkel Rosendahl1, Berit Jul Mosgaard1, 2 & Karina Dahl Steffensen3, 4 1) Gynækologisk-onkologisk Team, Gyækologisk klinik, Rigshospitalet 2) Det Sundhedsvidenskabelige Fakultet, Københavns Universitet 3) Onkologisk Afdeling, Vejle Sygehus 4) Institut for Regional Sundhedsforskning, Syddansk Universitet Ugeskr Læger 2018;180:V03170213
Reference: 
Ugeskr Læger 2018;180:V03170213
Blad nummer: 
Sidetal: 
2-6
Treatment of primary and recurrent ovarian cancer
With 550 new cases/year ovarian cancer constitutes 3% of all cancers among women. The unspecific symptoms cause delayed diagnosis and hence poor survival rates. Screening initiatives have been disappointing. In order to accelerate diagnosis and correct surgical management, patients are referred to centralized, specialized units. The primary treatment comprises surgical total cytoreduction followed by platinum-based chemotherapy. Newer biological agents are added when randomized trials have shown a benefit. Recurrence is managed by chemotherapy alone or repeated radical surgery followed by chemotherapy.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Frede Simonsen | 20/04
2 kommentarer
af Hans Storm Erichsen | 19/04
1 Kommentar
af Debatred. | 15/04
1 Kommentar
af Martin Bonde Petersen | 15/04
1 Kommentar
af Anne Lisbeth Hoffmann | 15/04
4 kommentarer
af Jørgen Lous | 13/04
9 kommentarer
af Karin Marlen Moldrup | 13/04
3 kommentarer